Windward Bio Prepares $175M IPO: Freedom Valuation

Stock Market News

13 November 2026, 13:41

Switzerland’s Windward Bio Group AG, which develops long-acting therapies for asthma and other inflammatory diseases, plans to raise about $174.9 million in an IPO. The company is offering roughly 10.3 million shares at $16–18 and expects to begin trading on Nasdaq on November 13 under the ticker WWB. At the same time, France’s Sanofi intends to invest an additional $50 million in the company through a private placement.

At a price of $17 per share, Windward’s market capitalization after the IPO and the concurrent placement would be about $986.6 million. The lead underwriters are Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank.

Betting on less frequent dosing

Windward Bio is developing antibodies to treat severe respiratory and skin diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. The company aims to reduce injection frequency compared with existing treatments.

Its lead candidate, WIN378, targets TSLP, a protein involved in triggering inflammatory responses. The already approved drug Tezspire is directed at the same target. However, Windward is developing WIN378 for dosing twice a year, whereas Tezspire is administered every four weeks.

Less frequent injections could make treatment more convenient for patients. But WIN378 remains an experimental drug: its efficacy and safety still need to be confirmed in further trials.

Next readouts expected in 2027

WIN378 is being evaluated in the Phase 2/3 POLARIS-1 study in severe uncontrolled asthma. In September, Windward reported positive interim Phase 2 results: the company observed improved lung function and reduced inflammatory markers. Based on these data, it selected dose levels and initiated Phase 3.

The next major Phase 2 results are expected in the first half of 2027. Windward plans to receive the Phase 3 POLARIS-1 results in the first half of 2029. Enrollment in the second Phase 3 study, POLARIS-2, is expected to begin in the first half of 2027.

Separately, WIN378 is being studied in COPD in the Phase 2 SIRIUS trial. Results are expected in the second half of 2027.

Second candidate targets two pathways

Another Windward program is WIN027, a bispecific antibody. It simultaneously targets TSLP and IL-13, two proteins involved in inflammatory processes. The company believes this approach could deliver a more pronounced and longer-lasting effect, though this still needs to be validated.

WIN027 is in a Phase 1 trial in healthy volunteers. Full results from this stage are expected in the first half of 2027. Enrollment for studies in COPD and atopic dermatitis is also planned for the same period.

Sanofi to invest an additional $50 million

In addition to the IPO, Windward agreed to a private placement for Sanofi. The pharmaceutical company will purchase shares and prepaid warrants totaling $50 million. This transaction is expected to close concurrently with the IPO.

As a result, if priced at the midpoint of the range, Windward could raise about $225 million before underwriting commissions and expenses. The company estimates net proceeds from the two transactions at approximately $203.8 million.

Previously, Windward raised $310 million in equity financing. Its investors include Novo Holdings, OrbiMed, Blue Owl, and RTW Investments.

The company is not yet generating product revenue

Windward is in the clinical development stage and does not yet have any products approved for commercial sale. For the first half of 2026, its net loss totaled $42.6 million, compared with $22.8 million a year earlier.

The proceeds from the IPO and the private placement, together with existing resources, will be used primarily to fund trials of WIN378 and WIN027. Windward estimates the financing will last into the first half of 2029. This outlook depends on trial timelines and actual spending.

For investors, the key catalysts will be clinical-trial results. Positive early-stage data do not guarantee success in later studies or approval for sale. Development delays and rising costs may also require additional financing.

Not an individual investment recommendation.

16, Dostyk street, integral non-residential facility No.2, Yessil district Astana, Republic of Kazakhstan (Talan Towers Offices).

+7 7172 67 77 55 - Free from landline numbers in Kazakhstan; calls from international and mobile numbers are chargeable.

(+7 727 3557555 – additional)

7555 - free from mobile operators in Kazakhstan [email protected], [email protected]

Notify about fraudulent activities or security issues regarding this resource: fbroker.kz/trustcenter

Owning securities and other financial instruments is always associated with risks: the value of securities and other financial instruments can both rise and fall. Past investment results do not guarantee future income. In accordance with the law, the company does not guarantee or promise future returns on investments, nor does it provide guarantees regarding the reliability of potential investments or the stability of potential income.

Freedom Finance Global PLC provides brokerage (agency) services in the securities market on the territory of the Astana International Financial Center (hereinafter referred to as AFSA) in the Republic of Kazakhstan. Subject to compliance with requirements, conditions, restrictions and/or directions of the Acting Law of the AFSA, the Company is authorized to conduct the following Regulated Activities under License No. AFSA-A-LA-2020-0019: Dealing in Investments as Principal, Dealing in Investments as Agent, Managing Investments, Advising on Investments, Arranging Deals in Investments.

S&P Global ratings – “BB-”, outlook “Positive”.

Ownership of securities and other financial instruments always involves risks: the cost of securities and other financial instruments may rise or fall. Past investment results do not guarantee future returns. In accordance with the legislation, the company does not guarantee or promise the profitability of investments in the future, does not guarantee the reliability of possible investments and the stability of the amount of possible income.

The information on the website is updated as part of keeping the data up-to-date and meeting regulatory disclosure requirements. Please note that these updates are for informational purposes only and are not marketing materials!